Simplify the transition from early iPSC drug discovery to translational programs with end-to-end iPSC engineering, differentiation, and cell banking services
With a long heritage in both iPSC technology and genome engineering, ASC brings deep expertise to advance your iPSC drug discovery programs toward the clinic and beyond.
Whether you start with our powerful TARGATT™ plug-and-play iPSC platform, leverage our off-the-shelf hypoimmunogenic iPSC lines for faster allogeneic development, or bring your own cells, our experienced team will engineer and differentiate your iPSCs to rapidly generate the functional cell types needed for your discovery and efficacy studies.
And when your program is ready to move forward, ASC will seamlessly transition your project to GMP development, rebuilding and differentiating your cells in our cleanrooms to generate materials suitable for IND-enabling studies and clinical programs.
Off-the-shelf GMP and matching research iPSCs
Our off-the-shelf iPSCs are reprogrammed from CD34+ cord blood cells (male)
Genome engineering technologies
With the proven ability to knock-in 50 kb at the H11 safe harbor site, TARGATT™ technology enables insertion of multiple genes and expression cassettes.
Differentiated cell types and applications
Interested in iPSC-derived cells for screening? Visit our iPSC-derived cells page or view our iPSC gene editing services for custom cell lines.
When you trust your iPSC engineering to ASC, you open the door to larger possibilities.
With TARGATT™ technology, we’ve proven that we can knock-in as much as 50 kb, enabling insertion of multiple full-length genes and multi-gene expression cassettes. Design logic-gated CARs, knock-in immune evasion elements, insert large, full-length genes.
We also have extensive experience editing iPSCs with CRISPR Cas9 and MAD7 if you need additional knockouts or point mutations.
If you’d like us to engineer your iPSC line, we can still help you leverage the power of TARGATT™ technology. We’ll use MAD7 to insert a landing pad before using TARGATT™ technology to deliver your payload.
See how TARGATT™ technology enables efficient knock-in of a 50 kb construct into human iPSCs, expanding the possibilities for complex genome engineering, demonstrating construction of an allogeneic therapy, and accelerating advanced cell line development.
Through proprietary iPSC handling and culture processes, we ensure viability, genomic stability, and pluripotency at every stage of genome engineering.
Tuj1 staining indicates differentiation of iPSCs into cortical neurons. (Top panel) Tuj1 staining in red, (bottom panel) Tuj1 (red), DAPI (blue) merge.
Engineering the right iPSC line is only the first step. ASC’s long heritage in iPSC technology is the foundation for our deep expertise in differentiating engineered iPSCs into functional cell types.
With robust differentiation protocols across a range of therapeutic areas—including neural, immune, cardiovascular, and other specialized cell types—and customizable characterization assays, we drive iPSC drug discovery programs.
Because differentiation protocols are tightly integrated with our genome engineering workflows, we can rapidly translate engineered iPSC platforms into functional cells suitable for disease modeling, screening, and proof-of-concept studies—helping your team move quickly from genetic design to biological validation.
As promising programs move toward translation, robust cell banking becomes critical to ensure consistency, traceability, and scalability. ASC provides comprehensive research and cGMP-grade cell banking services to support the transition from discovery programs to clinical development.
Our team can generate master and working cell banks tailored to your program requirements, with customizable bank size, vial concentration, and quality testing. All banking activities are performed in our California facility with controlled environments and continuous monitoring to ensure high standards of quality and reproducibility.
By integrating genome engineering, differentiation, and cell banking within a single workflow, ASC enables teams to seamlessly advance engineered iPSC platforms from early discovery through IND-enabling development and clinical manufacturing.
Find out how our integrated iPSC drug discovery platform can enable your projects by submitting the form below. We will get back to you within one business day.
